The invention refers to a new compound that inhibits RET, which is recombined during blood transfusion,A pharmaceutical ingredients containing these substances, their preparation procedures, and standardized procedures for sensitivity for treatment, monotherapy or political therapy, Treatment of gastrointestinal motility and / or secretion and / or abdominal diseases and / or disorders related to intestinal disorders and / or disorders related to intestinal disorders, or where modulation of intestinal activity can bring therapeutic benefits, including, but not limited to, all classifications of colon syndrome Irritable, irritableIncluding the deposition mode of diarrhea, mainly constipation or alternation, meteor shower, functional constipation, functional diarrhea, functional colonic stimulation, functional abdominal pain syndrome, chronic mental disease constipation, functional esophageal disorder, Functional gastrointestinal disorders, functional anorexic pain, intestinal inflammation, and diffuse diseases, such as non micro lung cancer, liver cancer, rectal cancer, spinal cord thyroid cancer, thyroid cancer, Yeltsin cancer, thyroid cancer, Ana type thyroid cancer, mumps thyroid cancer, brain tumor,Peritoneal cavity cancer, solid tumor, other lung cancer, head and neck cancer, blood cell cancer, neuroma, von Hippel Lindau syndrome and renal cancer, breast cancer, fallopian tube cancer, ovarian cancer, transitional cell cancer, prostate cancer, RET ribbons with increased activity in esophageal and gastrointestinal cancer, cholangiocarcinoma and adenocarcinoma, as well as in any malignant tumor.Esta invención se refiere a nuevos compuestos que son inhibidores de la cinasa RET (reorganizado durante la transfección), a composiciones farmacéuticas que los contienen, a procedimientos para su preparación, y a su uso para tratamientos, en monoterapia o en politerapia, para la normalización de la sensibilidad, movilidad y/o secreción gastrointestinal y/o trastornos o enfe
